Knowledge Home Human Health Knowledge All Opinion Papers Popular science Interviews Apply Home Human Health Knowledge Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results Home Human Health Knowledge Safety and Immunogenicity of PHH-1V Booster Against SARS-CoV-2 Variants, Including Omicron Subvariants: Results from a Phase IIb Open-Label Extension Study Home Human Health Knowledge Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial Home Human Health Knowledge Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2 Home Human Health Knowledge Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate Home Human Health Knowledge Preclinical evaluation of PHH-1V candidate against SARS-CoV-2 in non-human primates Home Human Health Knowledge RBDCOV Talks HIPRA’s participation: In 5 minutes, what is a recombinant protein vaccine? Home Human Health Knowledge RBDCOV: The project’s origins and future endeavours Home Human Health Knowledge Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19 Load more
